Department of Radiation Oncology, The University of Iowa, Iowa City, Iowa.
Department of Radiation Oncology, The University of Iowa, Iowa City, Iowa.
Pract Radiat Oncol. 2019 Mar;9(2):e156-e163. doi: 10.1016/j.prro.2018.10.012. Epub 2018 Nov 8.
This study aimed to examine the feasibility of stereotactic body radiation therapy (SBRT) as an external beam radiation therapy boost to positron emission tomography (PET) positive lymph nodes (LN) in patients with cervical cancer and to evaluate overall tumor control probability (TCP) increase.
Ten patients with cervical cancer and PET positive LN metastasis who received external beam radiation therapy (45 Gy), followed by a 3-dimensional conformal radiation therapy boost (5.4-9 Gy) and tandem-and-ovoid high-dose-rate brachytherapy (16-30 Gy) were retrospectively enrolled in this study. SBRT plans were generated using 21 Gy, 24 Gy, or 30 Gy as a replacement for 3-dimensional conformal radiation therapy boost. The 2 Gy-per-fraction equivalent dose maps were made using an α/β value of 10 for PET positive LNs and 3 for organs at risk (OARs). TCP values were calculated using a logistic TCP model, where 2 input parameters (D and Gamma = 2) were modeled by 2 clinical outcomes: our institution and the literature. OAR sparing was evaluated using Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) dose limits.
Thirty percent of 10 patients receiving conventional boost experienced recurrence. The TCP of the SBRT schemes was 88% ± 7% (97% ± 2%; 21 Gy), 96% ± 1% (99% ± 0%; 24 Gy), and 99% ± 1% (100% ± 0%; 30 Gy), and the conventional LN-boost TCP value was 25% ± 11% (58% ± 15%) when TCP input parameters were based on published clinical outcome data for LN SBRT treatments (institutional outcome data). The tumor coverage doses (D90) of the SBRT boost plans were on average 32.34 Gy (21 Gy), 37.78 Gy (24 Gy), and 55.54Gy (30 Gy) higher than the conventional LN boost plan. The QUANTEC OAR dose constraints were met for the bladder, rectum, and bowel in all cases for the SBRT LN 21 Gy group, and in 90% and 70% of cases in the SBRT LN 24 Gy and SBRT LN 30 Gy groups, respectively.
An SBRT boost dose of 30 Gy can be delivered without compromising QUANTEC OAR limits. The use of SBRT increases TCP values, regardless of the input parameters.
本研究旨在探讨立体定向体部放射治疗(SBRT)作为正电子发射断层扫描(PET)阳性淋巴结(LN)的外部束放射治疗增敏剂的可行性,并评估整体肿瘤控制概率(TCP)的提高。
本研究回顾性纳入了 10 例宫颈癌 PET 阳性 LN 转移患者,这些患者接受了外部束放射治疗(45Gy),随后接受了三维适形放射治疗增敏(5.4-9Gy)和串联和卵圆高剂量率近距离放射治疗(16-30Gy)。SBRT 计划使用 21Gy、24Gy 或 30Gy 替代三维适形放射治疗增敏。采用 α/β 值为 10 用于 PET 阳性 LN 和 3 用于危及器官(OAR)的 2Gy 等效剂量图。TCP 值使用逻辑 TCP 模型计算,其中 2 个输入参数(D 和 Gamma=2)通过 2 个临床结果建模:我们机构和文献。使用定量分析正常组织效应在临床(QUANTEC)剂量限制评估 OAR 保护。
10 例接受常规增敏的患者中有 30%出现复发。SBRT 方案的 TCP 为 88%±7%(97%±2%;21Gy)、96%±1%(99%±0%;24Gy)和 99%±1%(100%±0%;30Gy),当 TCP 输入参数基于 LN SBRT 治疗的已发表临床结果数据(机构结果数据)时,常规 LN-增敏 TCP 值为 25%±11%(58%±15%)。SBRT 增敏计划的肿瘤覆盖剂量(D90)平均比常规 LN 增敏计划高 32.34Gy(21Gy)、37.78Gy(24Gy)和 55.54Gy(30Gy)。在所有情况下,SBRT LN 21Gy 组的膀胱、直肠和肠的 QUANTEC OAR 剂量限制均得到满足,而 SBRT LN 24Gy 和 SBRT LN 30Gy 组的分别有 90%和 70%的病例得到满足。
可以在不损害 QUANTEC OAR 限制的情况下给予 30Gy 的 SBRT 增敏剂量。使用 SBRT 会增加 TCP 值,无论输入参数如何。